Feasibility and validity of using self-collected capillary blood using Tasso+ for measuring Alzheimer's Disease plasma-based biomarkers among underrepresented populations
While self-collected capillary blood using the Tasso+ device with a 24-hour delay demonstrates high feasibility and excellent validity for measuring GFAP and NfL biomarkers in underrepresented populations, it currently yields unreliable results for Aβ and pTau217 due to hemolysis and processing delays, necessitating optimized pre-analytics before widespread deployment.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Imagine you want to check the health of your brain for Alzheimer's disease. Traditionally, this has been like trying to get a sample of water from the bottom of a deep, dark well: you have to visit a special hospital, undergo an invasive spinal tap (collecting fluid from your spine), or get a very expensive brain scan. This is hard to do, especially if you live far away in a rural area, don't have a car, or feel nervous about medical procedures. As a result, many people who need these tests the most—such as those from Black, Hispanic, or lower-income communities—are often missing from the research.
Scientists wanted to see if there was an easier way. They tested a device called Tasso+, which looks a bit like a high-tech bandage. Instead of a needle in your arm, you stick this device to your upper arm, press a button, and it gently pricks your skin to collect a tiny drop of blood into a small tube. You can do this at home, seal the tube, and mail it to a lab.
The researchers asked: Is this "mail-in blood test" a good substitute for the traditional clinic blood draw, especially for underrepresented groups?
Here is what they found, broken down simply:
1. The "User Experience" (How it felt)
Think of the Tasso+ device like a new, tricky kitchen gadget.
- The Good: Most people found it easy to use and much less painful than a standard needle. It felt like a quick pinch rather than a deep poke.
- The Bad: Even though it was easy, many people (especially Black participants and those with less formal education) still preferred the old-fashioned clinic visit.
- Why? They didn't trust the "mail-in" part. They worried about the sample getting lost, stolen, or spoiling in the mail. They also found the instructions a bit confusing (like trying to assemble furniture without a clear manual). For many, the comfort of a trusted nurse in a clinic outweighed the convenience of doing it at home.
2. The "Science Test" (Did the blood work?)
The researchers compared the blood collected at home (Tasso+) with blood collected at the clinic (Venipuncture). They looked at six different "markers" (chemicals in the blood that tell a story about Alzheimer's).
Think of these markers like different types of messages in a bottle. Some messages are sturdy; others are fragile.
The Sturdy Messages (GFAP and NfL):
These two markers are like rocks. They are tough. Whether the blood sat in a mailbox for 24 hours or went straight to the lab, these markers stayed the same. The home-collected blood gave almost the exact same results as the clinic blood. Verdict: This method works great for these specific markers.The Fragile Messages (Amyloid Beta Aβ40 & Aβ42):
These markers are like fresh fruit. If you leave them in the mail for 24 hours, they rot. The study found that by the time the home-collected blood arrived at the lab, these markers had degraded significantly. The home test showed much lower levels than the clinic test. Verdict: This method is currently not reliable for these markers without better packaging (like keeping the blood cold).The Confusing Message (pTau217):
This is the most important marker for Alzheimer's, but it was the most chaotic. The home-collected blood didn't just show lower levels; it showed wildly higher levels (over 2,000% higher in some cases) compared to the clinic. It was like the mail-in process scrambled the message entirely. Verdict: This method is currently not reliable for this marker.
3. The "Why" (What went wrong?)
The study found two main reasons the fragile markers failed:
- Time: The blood sat at room temperature for 24 hours (simulating an overnight mail delivery). This is too long for the fragile markers; they break down or change.
- Hemolysis: This is a fancy word for "broken red blood cells." Because the Tasso+ device pricks the skin to get blood, it sometimes breaks more cells than a standard needle does. When cells break, they spill their contents, which messes up the chemical measurements.
The Bottom Line
The study concludes that while the Tasso+ device is a promising tool for making research more accessible, it isn't a "one-size-fits-all" solution yet.
- It works well for measuring GFAP and NfL (the sturdy markers).
- It does not work well for Amyloid Beta or pTau217 (the fragile or scrambled markers) unless the blood is kept cold and handled very carefully.
Most importantly, the study highlighted that trust and simplicity matter. Even if the science works, people from underrepresented communities won't use the tool if they don't trust the process or find the instructions too hard to follow. To make this work for everyone, researchers need to improve the instructions, address fears about mailing blood, and figure out how to keep the blood samples cool during transit.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.